MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
$38,970K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Increase in accounts payable and...
Stock-based compensation
Proceeds from maturity of held-t...
Others
Negative Cash Flow Breakdown
Increase in inventory
Investment in held-to-maturity s...
Increase in accounts receivable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income
7,781
19,777
23,037
390,895
Loss on extinguishment of debt
0
-9,153
0
0
Stock-based compensation
27,875
19,950
15,651
17,686
Depreciation and amortization
53
32
21
17
Amortization of premium (discount) on investment securities
254
367
383
786
Amortization of debt issuance costs
247
285
304
304
Amortization of leasehold interest
43
48
46
45
Deferred income taxes
708
3,864
18,627
-366,627
Noncash change in lease liability and right of use asset
441
573
432
431
Change in fair value of equity investments
1,227
1,534
-433
420
Change in fair value of notes payable
-524
-88
136
-14
Change in inventory reserve
-
-
6,171
-
Increase in inventory
66,824
13,275
-563
-8,695
Decrease (increase) in other current assets
-13,573
-10,661
1,911
30,632
Increase in accounts receivable
9,519
86,418
40,244
33,868
Decrease in income taxes payable
-6,133
-6,718
-
-
Increase in accounts payable and accrued expenses
65,347
34,016
2,008
-17,280
Decrease in lease liabilities
-408
-424
-519
-519
Decrease in other current liabilities
-262
-1,617
266
-277
Increase in deferred revenue
7,298
-5,988
-4,706
9,169
Net cash provided by (used in) operating activities
39,263
-17,894
19,660
-23,153
Proceeds from maturity of held-to-maturity securities
17,750
11,250
30,000
77,750
Investment in held-to-maturity securities
16,427
21,063
45,571
31,307
Purchases of equity investments
0
0
0
0
Purchases of property, plant and equipment
293
51
67
80
Net cash used in investing activities
1,030
-9,864
-15,638
46,363
Payment of loan payable
0
-255,000
0
0
Issuance of common stock, net
-
-
0
-
Proceeds from exercise of options
85
763
1,058
0
Proceeds from debt financings, net of debt discount costs
0
747,656
0
0
Financing costs paid
0
2,598
0
0
Purchase of treasury stock
0
99,992
0
78,242
Net cash provided by (used in) financing activities
85
390,829
1,058
-78,242
Net increase (decrease) in cash, cash equivalents and restricted cash
40,378
363,071
5,080
-55,032
Cash, cash equivalents and restricted cash at beginning of period
443,561
80,490
75,410
181,192
Cash, cash equivalents and restricted cash at end of period
483,939
443,561
80,490
75,410
Cash and cash equivalents
482,575
-
-
-
Restricted cash
1,364
-
-
-
Total cash, cash equivalents and restricted cash
483,939
-
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Increase in accounts
payable and accrued...
$65,347K
(-8.16%↓ Y/Y)
Proceeds from maturity of
held-to-maturity securities
$17,750K
(-86.32%↓ Y/Y)
Proceeds from exercise of
options
$85K
(-81.24%↓ Y/Y)
Stock-based compensation
$27,875K
(-11.04%↓ Y/Y)
Decrease (increase) in
other current assets
-$13,573K
(-237.28%↓ Y/Y)
Net income
$7,781K
(-76.60%↓ Y/Y)
Increase in deferred
revenue
$7,298K
(278.72%↑ Y/Y)
Deferred income taxes
$708K
Change in fair value of
notes payable
-$524K
(-251.68%↓ Y/Y)
Noncash change in lease
liability and right of use...
$441K
(-50.17%↓ Y/Y)
Amortization of debt issuance
costs
$247K
(-59.38%↓ Y/Y)
Depreciation and
amortization
$53K
(152.38%↑ Y/Y)
Amortization of leasehold
interest
$43K
(-54.26%↓ Y/Y)
Net cash provided by
(used in) operating...
$39,263K
(284.52%↑ Y/Y)
Net cash used in
investing activities
$1,030K
(106.09%↑ Y/Y)
Net cash provided by
(used in) financing...
$85K
(100.68%↑ Y/Y)
Canceled cashflow
$84,627K
Canceled cashflow
$16,720K
Net increase
(decrease) in cash, cash...
$40,378K
(179.56%↑ Y/Y)
Increase in inventory
$66,824K
(56.46%↑ Y/Y)
Increase in accounts
receivable
$9,519K
(-90.70%↓ Y/Y)
Decrease in income taxes
payable
-$6,133K
Change in fair value of
equity investments
$1,227K
(530.53%↑ Y/Y)
Decrease in lease
liabilities
-$408K
(61.55%↑ Y/Y)
Decrease in other current
liabilities
-$262K
(88.95%↑ Y/Y)
Amortization of premium
(discount) on investment...
$254K
(-90.30%↓ Y/Y)
Investment in
held-to-maturity securities
$16,427K
(-88.70%↓ Y/Y)
Purchases of property,
plant and equipment
$293K
(337.31%↑ Y/Y)
Buy us a coffee
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)